Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS-Reference-Cited by-同舟云学术

Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS

Published:2018-06-29 Issue:8 Volume:32 Page:1874-1878
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Alberti Michael O.^ORCID,Srivatsan Sridhar Nonavinkere,Shao Jin,McNulty Samantha N.,Chang Gue Su,Miller Christopher A.^ORCID,Dunlap Jennifer B.,Yang Fei,Press Richard D.^ORCID,Gao Qingsong,Ding Li^ORCID,Heusel Jonathan W.,Duncavage Eric J.,Walter Matthew J.^ORCID

Funder

Lottie Caroline Hardy Trust

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0193-y.pdf

Reference15 articles.

1. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.

2. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.

3. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12.